|
Distaclor (cefaclor
monohydrate USP) is a semisynthetic cephalosporin antibiotic for oral
administration.
Distaclor is indicated in the treatment of the following
infections when caused by susceptible strains of the designated
micro-organisms:
- Otitis media caused by S. pneumoniae, H. influenzae,
staphylococci, S. pyogenes (group A β-hemolytic streptococci), and M.
catarrhalis.
- Lower respiratory infections, including pneumonia caused by S.
pneumoniae, H. influenzae, S. pyogenes (group A β-hemolytic
streptococci), and M. catarrhalis.
- Upper respiratory infections, including pharyngitis and
tonsillitis caused by S. pyogenes (group A β-hemolytic streptococci),
and M. catarrhalis.
- Urinary tract infections, including pyelonephritis and cystitis
caused by E. coli, P. mirabilis, Klebsiella spp. and coagulase-negative
Staphylococci.
Note: Distaclor has been found to be effective in both acute and
chronic urinary tract infections.
- Skin and skin structure infections caused by staphylococcus
aureus and S. pyogenes (group A β- hemolytic streptococci).
- Sinusitis
- Gonococcal urethritis.
Appropriate culture and susceptibility studies should be performed to
determine susceptibility of the causative organism to Distaclor.
______________________________________________________________________________________________
Aleppo Pharmaceutical Company (ALPHA) is Syria's leading
manufacturer and distributor of pharmaceutical products. Providing high
quality products according to GMP requirements; regulations and ISO 9002
(Quality Management System).
Syrian Pharmaceutical Industries, Middle East, Syria Pharmaceutical
Industry, pharmacy, Medicaments, medical, Drugs, arab pharmaceutical
manufacturing, pharmaceutical companies, pharmaceutical sales.
If you have any questions about Distaclor that have not been
answered on this site send us an email or call ALPHA Pharmaceutical
Industry at + 963-21-2122424.
Copyright © ALPHA – Aleppo Pharmaceutical Industries, Aleppo-Syria -
Distaclor. All rights reserved
Web Design by
Syrian Web Solutions |